Trial Profile

Neoadjuvant Letrozole and Lapatinib in Postmenopausal Women With ER and Her2 Positive Breast Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapatinib (Primary) ; Letrozole (Primary)
Indications Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms Neo-All-In

Most Recent Events

11 Oct 2016 Results of explorative mutational analysis (n=21) presented at the 41st European Society for Medical Oncology Congress.
19 Nov 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
21 Jan 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com